Investor Relations

Corporate Profile

We are a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program AKR-001 to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.

Copyright West LLC. Minimum 15 minutes delayed.

Recent News

October 3, 2019

Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight™ Human Liver Disease platform

3D InSight™ Human Liver Disease Platform will be used to screen effects of Akero lead program AKR-00...

September 4, 2019

Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference

SAN FRANCISCO , Sept. 4, 2019 /PRNewswire/ --  Akero Therapeutics, Inc.  (Nasdaq: AKRO), a clinical-...

August 12, 2019

Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results

-- Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH -- -- Raised $98.4 million in aggr...

July 2, 2019

Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)

SAN FRANCISCO , July 2, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-sta...

June 24, 2019

Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO , June 24, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-st...

June 19, 2019

Akero Therapeutics Announces Pricing of Initial Public Offering

SAN FRANCISCO , June 19, 2019 /PRNewswire/ --  Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-s...